Lilly Rejects NICE Comparator For Efient In ACS, But Gains Approval Anyway
This article was originally published in The Pink Sheet Daily
Despite Lilly's decision not to make an indirect comparison its chosen comparator, AstraZeneca’s Brilinta, NICE agrees that Lilly's Efient is cost-effective and sometimes clinically superior to standard care.
You may also be interested in...
EFPIA is calling on its members to sign up to the European Commission’s multi HTA early dialogue initiative to harmonize some significant aspects of European reimbursement.
Plavix was a tough competitor before it went generic; now that cheap versions of the clot-buster are available, the market will prove even more challenging for the remaining branded antiplatelet drugs.
Lilly/Daiichi Sankyo's clot-buster Effient proved more cost-effective for acute coronary syndrome patients managed with percutaneous coronary intervention procedures than Bristol and Sanofi's soon-to-be generic Plavix in a large study funded by Lilly